RxDoctor Payments Data

Sandra Holloway, MD

Gastroenterology · Bend, ORNPI 1902898729

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,182 of the $3,604 with a category attached, or 88.3%. It is spread thinly across 27 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations.

$3,604in general payments, 2019–2025

Across 107 payments — averaging $33.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$839
  • AbbVie$582
  • Braintree Laboratories, Inc.$265
  • Lilly USA, LLC$229
  • Takeda Pharmaceuticals U.S.A., Inc.$178
  • Bristol Myers Squibb$163
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,18288%
  • Education$2096%
  • Gifts$2136%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,604 in reported general payments places this provider in the 85th percentile of 220 gastroenterology providers in Oregon.

See all gastroenterology providers in Oregon

Medicare billing

Part B allowed, 2024
$54,199
Medicare patients
222
Services billed
387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates64$4,291
Mesalamine DrMesalamine11$2,041
Sucralfate13$1,843
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,746
Omeprazole29$714
Pantoprazole Sodium38$520
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl31$417
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl18$284
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl13$233
Ondansetron Hcl32$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$265$1,74611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 220 gastroenterology providers in Oregon.

Other gastroenterology in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →